STICs and STONes: A Randomised, Phase II, Double-Blind, Placebo-Controlled Trial of Aspirin in Chemoprevention of Ovarian Cancer in Women with BRCA1 and BRCA2 Mutations

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1122290

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Women with a BRCA1 or BRCA2 gene abnormality are at increased risk of ovary and fallopian tube (O&FT) cancers and often have their O&FTs removed to prevent cancer. Microscopic cancers are often seen at the time of surgery. Some studies suggest that aspirin might reduce O&FT cancer risk. This study will assign women to daily aspirin or placebo for 6-24 months before their preventive O&FT surgery. It will provide a better understanding of how O&FT cancers start and the influence aspirin may have.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2021

Funding Scheme: Project Grants

Funding Amount: $653,892.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Genetics

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

BRCA1 | aspirin | chemoprevention | clinical trial | ovarian cancer

Related Links